BioSpace News Archive

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will be supporting a colloquium titled “Recurrent Glioblastoma Management: Challenges and Opportunities” at this year’s ESMO Congress, held from September 27 to October 1 at the Fira Gran Via in Barcelona, Spain.

Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), provides a business update for the last twelve months.

Eisai Co., Ltd. announced that a series of abstracts will be presented during the European Society for Medical Oncology 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019.

MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, is pleased to announce that it will host a scientific lunch symposium titled “Local Therapies in Malignant Gliomas - update and new perspectives” during the 19th European Congress of Neurosurgery in Dublin, Ireland.

Apogenix announced that a new publication in Human Vaccines & Immunotherapeutics highlights the advantages of hexavalent CD40 agonists, such as HERA-CD40L, in the targeting of CD40 in immuno-oncology.

Firma Clinical Research, a niche service provider, is partnering with The Myositis Association on a multi-faceted project to better integrate the experience of patients into the training of clinical trial investigators and support providers.

According to a new study carried out at the University of Eastern Finland, the distribution of drug molecules within the brain can be improved by utilizing LAT1, which is expressed highly in the brain.

Artios Pharma Limited announces the appointment of Tania Dimitrova as Chief Business Officer and its expanded presence in the United States.

U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patientsbwith Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes